RxDoctor Payments Data

Mubashir Khan, MD

Neurology · Prince George, VANPI 1023087368

Payments from drug & device makers

$20,577in general payments, 2019–2025

Across 1,230 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biogen$2K
  • Novartis$1K
  • UCB, Inc.$1K
  • AstraZeneca$770
  • Supernus Pharmaceuticals, Inc.$741
  • plus $12K from 49 others

What the payments were for

  • Speaking & faculty fees$2311%
  • Food & beverage$20,22298%
  • Education$1231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,577 in reported general payments places this provider in the 75th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$223,016
Medicare patients
680
Services billed
8,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$200,869
AptiomEslicarbazepine Acetate26$52,753
Nurtec OdtRimegepant Sulfate23$42,264
Oxtellar XrOxcarbazepine21$41,719
Memantine Hcl ErMemantine Hcl208$33,406
Aimovig AutoinjectorErenumab-Aooe39$31,720
NuedextaDextromethorphan Hbr/Quinidine20$31,434
Carbamazepine ErCarbamazepine226$29,545
BriviactBrivaracetam17$27,785
Lamictal XrLamotrigine12$21,694
Emgality PenGalcanezumab-Gnlm22$15,326
Levetiracetam ErLevetiracetam172$14,510
VimpatLacosamide11$14,391
QuliptaAtogepant11$13,929
Sumatriptan Succinate134$13,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$638$200,86925 claims
Sunovion Pharmaceuticals Inc.Aptiom$532$52,75326 claims
PfizerNurtec Odt$710$42,26423 claims
UCB, Inc.Briviact, Vimpat$1,338$42,17628 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$741$41,71921 claims
Avanir Pharmaceuticals, Inc.Nuedexta$43$31,43420 claims
AbbVieQulipta$2,554$13,92911 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$714$8,66434 claims
Upsher-smith Laboratories LLCTopiramate$85$3,697290 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 neurology providers in Virginia.

Other neurology in Prince George

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →